Annals of Clinical Psychiatry

, Volume 12, Issue 1, pp 35–42 | Cite as

Hair Loss in Psychopharmacology

  • Yekaterina Mercke
  • Huaibao Sheng
  • Tehmina Khan
  • Steven Lippmann
Article
  • 206 Downloads

Abstract

Medication-induced alopecia is an occasional side effect of many psychopharmaceuticals. Most of the mood stabilizer and antidepressant drugs can lead to this condition. Some antipsychotic and antianxiety agents induce alopecia. Hair loss is also related to hypothyroidism, which can be induced by lithium and other agents. Alopecia might not be reported by some people, but physicians should be aware of this potential problem which may contribute to noncompliance. Lithium causes hair loss in 12–19% of long-term users. Valproic acid and/or divalproex precipitates alopecia in up to 12% of patients in a dose-dependent relationship. Incidences up to 28% are observed with high valproate concentration exposures. These pharmaceuticals also can change hair color and structure. The occurrence of carbamazepine-induced alopecia is at or below 6%. Hair loss is less common with other mood stabilizers. Tricyclic antidepressants, maprotilene, trazodone, and virtually all the new generation of antidepressants may on rare occasions lead to alopecia. The same applies to haloperidol, olanzepine, risperidone, clonazepam, and buspirone, but not to other neuroleptics, benzodiazepines, or barbiturates, selected antihistamines, and antiparkinsonians. Discontinuation of the medication or dose reduction almost always leads to complete hair regrowth. The therapeutic value of mineral supplements remains unclear.

alopecia hair loss lithium valproic acid/divalproex (valproate) carbamazepine psychopharmaceuticals 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Rook A, Dawber R (eds.): Diseases of the Hair and Scalp, 2nd ed. Oxford: Blackwell; 1982Google Scholar
  2. 2.
    Stroud JD: Diagnosis and management of the hair loss patient. Cutis 1987; 40(3):272–276Google Scholar
  3. 3.
    Reeves JT, Maibach HI: Drug and chemical induced hair loss. In: Marzulli FN, Maibach HI, eds. Advances in Modern Toxicology, Vol. 4. Dermatotoxicology and Pharmacology. Washington: Hemisphere; 1977; 488Google Scholar
  4. 4.
    Nielsen TA, Reichel M: Alopecia: Diagnosis and management. Am Family Phys 1995; 51:1513–1522Google Scholar
  5. 5.
    Tobin DJ, Orentreich N, Fenton DA, Bystryn JC: Antibodies to hair follicles in alopecia areata. J Invest Dermatol 1994; 102(5):721–724Google Scholar
  6. 6.
    Dunagin WG: Clinical toxicity of chemotherapeutic agents: Dermatologic toxicity. Semin Oncol 1982; 9:14–22Google Scholar
  7. 7.
    Pillans PL, Woods DJ: Review: Drug-associated alopecia. Int J Dermatol 1995; 34:149–158Google Scholar
  8. 8.
    Brodin MB: Drug-related alopecia. Dermatol Clin 1987; 5(3):571–579Google Scholar
  9. 9.
    Picard C, Jonville-Bera AP, Billard C, Autret E: Alopecia associated with gabapentin: First case [letter]. Ann Pharmacother 1997; 31(10):1260Google Scholar
  10. 10.
    Lampl Y, Gillad R, Savira-Pinchas I, Barak T: Hair loss–An adverse reaction to treatment with vigabatrin. Acta Ther 1996; 22:51–55Google Scholar
  11. 11.
    1999 Physicians' Desk Reference, 53rd ed. Montvale, NJ: Medical Economics; 1999Google Scholar
  12. 12.
    Srebrnik A, Hes JP, Brenner S: Adverse cutaneous reactions to psychotropic drugs. Act Derm Venereol (Stokh) 1991; 71(Suppl 158):3–12Google Scholar
  13. 13.
    Sarantidis D, Waters B: A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry 1983; 143:42–50Google Scholar
  14. 14.
    Orwin A: Hair loss following lithium therapy. Br J Dermatol 1983; 108:503–504Google Scholar
  15. 15.
    McCreadie RG, Morrison DP: The impact of lithium in South West Scotland: Demographic and clinical findings. Br J Psychiatry 1985; 146:70–74Google Scholar
  16. 16.
    Jefferson JW, Greist JH, Diamond RL: Lithium and hair loss. Int Drug Ther Newsl 1979; 14:23Google Scholar
  17. 17.
    Yassa R, Ananth J: Hair loss in the course of lithium treatment: A report of 2 cases. Can J Psychiatry 1983; 28:132–133Google Scholar
  18. 18.
    Mortimer PS, Dawber RP: Hair loss and lithium. Int JDermatol 1984; 23:603–604Google Scholar
  19. 19.
    Vestergaard P, Amdisen A, Schou M: Clinically significant side effects of lithium treatment: A survey in long-term treatment. Acta Psychiatr Scand 1980; 62:193–200Google Scholar
  20. 20.
    Silvestri A, Santonastaso P, Paggiarin D: Alopecia areata during lithium therapy. Gen Hosp Psychiatry 1988; 10:46–48Google Scholar
  21. 21.
    Bork K: Undesirable drug reactions affecting the hair and nails. In: Bork K, ed. Cutaneous Side Effects of Drugs. Philadelphia: Saunders; 1988: 249Google Scholar
  22. 22.
    Kirov G: Thyroid disorders in lithium-treated patients. J Affect Disord 1998; 50(1):33–40Google Scholar
  23. 23.
    Ramanathan M, Abidin MN, Muthukumarappan M: The prevalence of skin manifestations in thyrotoxicosis–A retrospective study. Med J Malaysia 1989; 44(4):324–328Google Scholar
  24. 24.
    Freinkel RK, Freinkel N: Hair growth and alopecia in hypothyroidism. Arch Dermatol 1972; 106(3):349–352Google Scholar
  25. 25.
    Signore RJ, von Weiss J. Alopecia of myxedema: Clinical response to levothyroxine sodium. JAmAcad Dermatol 1991; 25(5 Pt 2):902–904Google Scholar
  26. 26.
    Dawber RP, Mortimer PS: Hair loss during lithium treatment. Br J Dermatol 1982; 107:124–125Google Scholar
  27. 27.
    Kusumi Y: A cutaneous side effect of lithium. Dis Nerv Syst 1971; 32:853–854Google Scholar
  28. 28.
    Muniz CE, Salem RB, Director KL: Hair loss in a patient receiving lithium. Psychosomatics 1982; 23(3):312–313Google Scholar
  29. 29.
    Eustace DP: Lithium-induced reaction. Br J Psychiatry 1986; 148:752Google Scholar
  30. 30.
    Ghadirian AM, Lalinec-Michaud M: Report of a patient with lithium-related alopecia and psoriasis. J Clin Psychiatry 1986; 47(4):212–213Google Scholar
  31. 31.
    Wagner KD, Teicher MH: Lithium and hair loss in childhood. Psychosomatics 1991; 32(3):355–356Google Scholar
  32. 32.
    Davis R, Peters DH, McTavish D: Valproic acid.Areappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47(2):332–372Google Scholar
  33. 33.
    McKinney PA, Finkenbine RD, deVane LC: Alopecia and mood stabilizer therapy. Ann Clin Psychiatry 1996; 8:183–185Google Scholar
  34. 34.
    Klotz U, Schweizer C: Valproic acid in childhood epilepsy: Anticonvulsive efficacy in relation to plasma levels. Int J Clin Pharmacol 1980; 18(10):461–465Google Scholar
  35. 35.
    Despland PA: Tolerance to and unwanted effects of valproate sodium. Schweiz Rundschau Med Praxis 1994; 83(40): 1132–1139Google Scholar
  36. 36.
    Henriksen O, Johannessen SI: Clinical and pharmacokinetic observations on sodium valproate–A 5–year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65(5):504–523Google Scholar
  37. 37.
    Beydoun A, Sackellares JC, Shu V: Safety and efficacy of divalproex sodium monotherapy in partial epilepsy:A doubleblind, concentration-response design clinical trial. Neurology 1997; 48:182–188Google Scholar
  38. 38.
    Uehlinger C, Barrelet L, Touabi M, Baumann P: Alopecia and mood stabilizers: Two case reports. Eur Arch Psychiatry Clin Neurosci 1992; 242:85–88Google Scholar
  39. 39.
    Zaccara G, Campostrini R, Paganini M, Messori A, Valenza T, Arnetoli G, Zappoli R: Long-term treatment with sodium valproate: Monitoring of venous ammonia concentrations and adverse effects. Ther Drug Monitoring 1987; 9(1):34–40Google Scholar
  40. 40.
    Fatemi SH, Calabrese JR: Treatment of valproate-induced alopecia. Ann Pharmacother 1995; 29(12):1302Google Scholar
  41. 41.
    Healy MA, Aslam MA: The clinical significance of metal binding in convulsion control with sodium valproate. J Clin Hosp Pharmacy 1986; 11:189–198Google Scholar
  42. 42.
    Tasaki M, Hanada K, Hashimoto I: Analyses of serum copper and zinc levels and copper/zinc ratios in skin diseases. J Dermatol 1993; 20(1):21–24Google Scholar
  43. 43.
    Hurd RW, Van Rinsvelt HA, Wilder BJ, Karas B, Maenhaut W, De Reu L: Selenium, zinc, and copper changes in valproic acid: Possible relation to drug side effects. Neurology 1984; 34(10):1393–1395Google Scholar
  44. 44.
    Sozuer DT, Barutcu UB, Karakoc Y, Yalcin E, Onen S: The effects of antiepileptic drugs on serum zinc and copper levels in children. J Basic Clin Physiol Pharmacol 1995; 6:265–269Google Scholar
  45. 45.
    Kaji M, Ito M, Okuno T, Momoi T, Sasaki H, Yamanaka C, Yorifuji T, Mikawa H: Serum copper and zinc levels in epileptic children with valproate treatment. 1992; Epilepsia 33(3):555–557Google Scholar
  46. 46.
    Suzuki T, Koizumi J, Moroji T, Shiraishi H, Hori T, Baba A, Kawai N, Tada K: Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics. Biol Psychiatric 1992; 31:571–581Google Scholar
  47. 47.
    Kuzuya T, Hasegawa T, Shimizu K, Nabeshima T: Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. Int J Clin Pharmacol Ther Toxicol 1993; 31(2):61–65Google Scholar
  48. 48.
    Covanis A, Gupta AK, Jeavons PM: Sodium valproate: Monotherapy and polytherapy. Epilepsia 1982; 23(6):693–720Google Scholar
  49. 49.
    Bittencourt PR: Valproic acid, curly hair and weight gain. Arq Neuro-Psiquiatria 1986; 44(1):78–81Google Scholar
  50. 50.
    Jeavons PM, Clark JE, Harding GE: Valproate and curly hair [letter]. Lancet 1997; 1(8007):359Google Scholar
  51. 51.
    Mathew NT, Ali S: Valproate in the treatment of persistent chronic daily headache. An open label study. Headache 1991; 31(2):71–74Google Scholar
  52. 52.
    Herranz JL, Arteaga R, Armijo JA: Change in hair colour induced by valproic acid. Dev Med Child Neurol 1981; 23(3):386–387Google Scholar
  53. 53.
    Gupta AK: “Perming” effect associated with chronic valproate therapy. Br J Clin Pract 1988; 42(2):75–77Google Scholar
  54. 54.
    Verity CM, Hosking G, Easter DJ: A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37(2):97–108Google Scholar
  55. 55.
    Mattson RH, Cramer JA, Collins JF: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327:765–771Google Scholar
  56. 56.
    Shuper A, Stahl B, Weitz R: Carbamazepine-induced hair loss. Drug Intell Clin Pharm 1985; 19:924–925Google Scholar
  57. 57.
    Hilder RJ: Propranolol and alopecia. Cutis 1979; 24(1):63–64Google Scholar
  58. 58.
    Martin CM, Southwick EG, Maibach HI: Propranolol induced alopecia. Am Heart J 1973; 86:236Google Scholar
  59. 59.
    Scribner MD: Propranolol treatment. Arch Dermatol 1977; 113:1303Google Scholar
  60. 60.
    England JR, England JD: Alopecia and propranolol therapy. Aust Fam Physician 1982; 11(3):225–226Google Scholar
  61. 61.
    Ikeda A, Shibasaki H, Shiozaki A, Kimura J: Alopecia with carbamazepine in two patients with focal seizures. J Neurol Neurosurg Psychiatry 1997; 63(4):549–550Google Scholar
  62. 62.
    Warnock JK, Sieg K, Willsie D, Stevenson EK: Drug-related alopecia in patients treated with tricyclic antidepressants. J Nerv Ment Dis 1991; 179(7):441–442Google Scholar
  63. 63.
    Baral J, Deakins S: Imipramine-induced alopecia areata-like lesions. Int J Dermatol 1987; 26(3):198Google Scholar
  64. 64.
    Friedman M. Iatrogenic alopecia: J Fam Pract 1994; 39(2):114Google Scholar
  65. 65.
    Perini G, Zara M, Cipriani R, Carraro C, Preti A, Gava F, Coghi P, Peserico A: Imipramine in alopecia areata. A doubleblind, placebo-controlled study. Psychother Psychosom 1994; 61(3-4):195–198Google Scholar
  66. 66.
    Mareth TR: Hair loss associated with fluoxetine use in two family members. J Clin Psychiatry 1994; 55(4):163Google Scholar
  67. 67.
    Rapaport M, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L, Bradford D: A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16(5):373–378Google Scholar
  68. 68.
    Seifritz E, Hatzinger M, Muller MJ, Hemmeter U, Trachsler-Holsboer E: Hair loss associated with fluoxetine but not with citalopram. Can J Psychiatry 1995; 40(6):362Google Scholar
  69. 69.
    Ananth J, Elmishaugh A: Hair loss associated with fluoxetine treatment. Can J Psychiatry 1991; 36(8):621Google Scholar
  70. 70.
    McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH: Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. J Clin Psychopharmacol 1998; 18(1):62–66Google Scholar
  71. 71.
    Bourgeois J: Two cases of hair loss after sertraline use. J Clin Psychopharmacol 1996; 16(1):91–92Google Scholar
  72. 72.
    Jenike MA: Severe hair loss associated with fluoxetine use. Am J Psych 1991; 148:392Google Scholar
  73. 73.
    Ogilvie AD: Hair loss during fluoxetine treatment. Lancet 1993; 342(8884):1423Google Scholar
  74. 74.
    Gupta S, Major LF: Hair loss associated with fluoxetine. Br J Psychiatry 1991; 159:737–738Google Scholar
  75. 75.
    Bhatara VS, Gupta S, Freeman JW: Fluoxetine-associated paresthesias and alopecia in awoman who tolerated sertraline. J Clin Psychiatry 1996; 57:5Google Scholar
  76. 76.
    Parameshwar E: Hair loss associated with fluvoxamine use. Am J Psychiatry 1996; 153(4):581–582Google Scholar
  77. 77.
    Gupta S, Gilroy, Jr. WR: Hair loss associated with nefazodone. J Fam Pract 1997; 44(I):20–21Google Scholar
  78. 78.
    Rauch SL, O'sullivan RL, Jenike MA: Open treatment of obsessive-compulsive disorder with venlafaxine: A series of ten cases. J Clin Psychopharmacol 1996; 16:81–84Google Scholar
  79. 79.
    Kubota T, Ishikura T, Jibiki I: Alopecia areata associated with haloperidol. Jpn J Psychiatry Neurol 1994; 48(3):579–581Google Scholar
  80. 80.
    Alexander S: Diffuse alopecia in women. Trans Annu Rep St. Johns Hosp Dermatol Soc 1965; 51:99Google Scholar
  81. 81.
    Eckert J, Church RE, Ebling FJ, Munro DS: Hair loss in women. Br J Dermatol 1967; 79:543Google Scholar

Copyright information

© American Academy of Clinical Psychiatrists 2000

Authors and Affiliations

  • Yekaterina Mercke
    • 1
  • Huaibao Sheng
    • 1
  • Tehmina Khan
    • 1
  • Steven Lippmann
    • 1
  1. 1.Department of Psychiatry and Behavioral ScienceUniversity of Louisville School of MedicineLouisville

Personalised recommendations